CTRI/2022/07/043752
已完成
未知
A Prospective, Interventional, open label, Multicentric study to evaluate the efficacy and safety ofSilverNovaTM Skin Cream in Post aesthetic skin procedures subjects. - NI
Viridis BioPharma Pvt Ltd0 个研究点目标入组 60 人待定
概览
- 阶段
- 未知
- 干预措施
- 未指定
- 疾病 / 适应症
- Health Condition 1: L989- Disorder of the skin and subcutaneous tissue, unspecified
- 发起方
- Viridis BioPharma Pvt Ltd
- 入组人数
- 60
- 状态
- 已完成
- 最后更新
- 3年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •1\. Male and female subject between the age of 18 to 45 years.
- •2\. Patients must have undergone Post aesthetic skin procedures which include: Chemical peeling (Tri Chloroacetic acid (TCA) cross peel, Yellow peel, Black peel, Glycolic peel etc.), Laser hair removal and Microneedling radiofrequency for atrophic acne scars.
- •3\. The subjects were of general good health, had no obvious skin disease, known history of atopic dermatitis and/or skin elastosis on the face.
- •4\. Subjects must be able to read, understand and provide written informed consent.
- •5\. Individuals must agree to refrain from using any new products other than the assigned test materials.
- •6\. Willingness not to use any moisturizer, cleanser, and/or sunscreen on the face other than the provided study product.
- •7\. Subjects must agree to avoid excessive sun exposure and the use of artificial tanning methods.
- •8\. Subjects must agree to arrive at their study visits with a clean face and without any products (lotions, creams, makeup, etc.) applied to their face.
- •9\. Sexually active females of childbearing potential participating in the study must agree to use a medically\-acceptable method of contraception while receiving study product. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant; including perimenopausal women who are less than 2 years from their last menses.
- •10\. Subjects free of any acute or chronic illness/disease that might interfere with or increase risk of study participation.
排除标准
- •1\. Any dermatological disorder that, in the investigatorâ??s opinion, may interfere with the accurate evaluation of the subjectâ??s face.
- •2\. Subjects who have demonstrated a previous hypersensitivity reaction to any of the ingredients of the study products.
- •3\. Concurrent therapy with any medication, either topical or oral, that might interfere with the study.
- •4\. Subjects who have used a topical retinoid or other cosmeceutical preparation within 2 weeks of study enrollment, to include kojic acid, vitamin C, licorice extracts, alpha hydroxy acids etc.
结局指标
主要结局
未指定
相似试验
尚未招募
3 期
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of TreatmentCTRI/2024/07/069956Pfizer Inc.
暂停
3 期
A clinical study to evaluate the efficacy and safety of immunoglobulin intravenous (human) 10% (NewGam) in Primary Immune Thrombocytopenia, Is the condition of having an abnormally low platelet count (thrombocytopenia) of no known cause.Health Condition 1: null- Primary Immune Thrombocytopenia (ITP)CTRI/2011/11/002098OCTAPHARMA AG95
已完成
2 期
Clinical study on JP-16 Capsules in impotencyHealth Condition 1: null- erectile dysfunctionCTRI/2017/09/009618Chatarubhuj Pharmaceutical Co40
已完成
2 期
Clinical study on IMPERIM® Capsule in erectile dysfunction.Health Condition 1: N529- Male erectile dysfunction, unspecifiedCTRI/2019/09/021217Dr Bioveda Lab
已完成
2 期
Clinical study on Ayuvigo Forte Capsule in erectile dysfunctioCTRI/2017/08/009425Welex Laboratories Pvt Ltd38